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Secondary metabolites from actinomycetes especially the genus Streptomyces may be one of 
the most important sources for novel anticancer agents. A purified fraction from a novel 
actinomycete strain, Streptomyces sp. H7372, was elucidated in breast cancer cells. We have 
isolated three purified fractions from a novel strain, Streptomyces sp. H7372. One of the 
fractions, designated as 31-2, exhibited the strongest growth-inhibitory effect and thereby 
was selected for further studies. 31-2 exerted a growth-inhibitory effect on a panel of 15 
human cancer and 2 non-malignant cell lines. In MCF-7 and MDA-MB-231 breast cancer 
cells, 31-2 induced a cytostatic (anti-proliferative) effect without causing cytotoxicity (cell 
death). Our data suggest that the cytostasis resulted from cell cycle arrest at the G1 phase in 
MCF-7 cells and at the S phase in MDA-MB-231 cells. Western blot analysis demonstrated a 
modulation of phosphorylation of the Rb and CDC2 proteins and of CDK4, cyclin D1 and 
cyclin D3 in the 31-2-treated breast cancer cell lines. The protein levels of CDK2, CDK6, and 
PCNA were not affected by 31-2 treatment. 31-2 also exhibited an anti-invasive effect in 
MDA-MB-231 cells. However, this effect is not attributed to the modulation of proteolytic 
activity in MDA-MB-231 cells as the enzymatic degradation of type IV collagen was not 
affected by 31-2. The 31-2 is a potent cytostatic and anti-invasive agent and modulates the 
cell cycle pathway. Together, these results will have important implications in searching for 
novel approaches to treat cancer. 
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